Compare Sana Biotechnology Inc (SANA) vs Wayfair Inc (W) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Wayfair Inc — how do they compare? Sana Biotechnology Inc trades at $3.76 (market cap $1.13B), while Wayfair Inc trades at $103.6 (market cap $14.14B). The key difference: Wayfair Inc is far larger — about 12.5× Sana Biotechnology Inc's market cap, and Wayfair Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| SANA | W | |
|---|---|---|
Market Cap | $1.13B | $14.14B |
Sector | Health | Consumer Cyclical |
52-Week High | $5.92 | $119.05 |
52-Week Low | $2.68 | $57.40 |
Enterprise Value | $1.05B | $16.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
Wayfair (W) trades at $103.59, up 0.25% with bullish technical signals including a golden cross pattern. The company reported strong Q2 2026 results with EPS of $0.95 beating estimates and 7.5% revenue growth. Despite negative net margins, operating cash flow improved to $534 million in 2025. Analyst consensus leans bullish with 52% buy ratings and a $122 price target representing 18% upside potential.
The outlook remains positive driven by U.S. market share gains and margin expansion guidance, though risks include persistent losses and high debt levels. Technical support at $102 provides near-term protection while resistance at $105-108 marks the next challenge. The stock's momentum appears sustainable if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →
